@article{769347e7c8c443cabc4fa9410574701b,
title = "Automated measurement of liver attenuation to identify moderate-to-severe hepatic steatosis from chest CT scans",
abstract = "Purpose: Develop and validate an automated method for measuring liver attenuation in non-contrast low-dose chest CT (LDCT) scans and compare it to the standard manual method for identifying moderate-to-severe hepatic steatosis (HS). Method: The automated method identifies a region below the right lung within the liver and uses statistical sampling techniques to exclude non-liver parenchyma. The method was used to assess moderate-to-severe HS on two IRB-approved cohorts: 1) 24 patients with liver disease examined between 1/2013–1/2017 with non-contrast chest CT and abdominal MRI scans obtained within three months of liver biopsy, and 2) 319 lung screening participants with baseline LDCT performed between 8/2011–1/2017. Agreement between the manual and automated CT methods, the manual MRI method, and pathology for determining moderate-to-severe HS was assessed using Cohen's Kappa by applying a 40 HU threshold to the CT method and 17.4% fat fraction to MRI. Agreement between the manual and automated CT methods was assessed using the intraclass correlation coefficient (ICC). Variability was assessed using Bland-Altman limits of agreement (LoA). Results: In the first cohort, the manual and automated CT methods had almost perfect agreement (ICC = 0.97, κ = 1.00) with LoA of −7.6 to 4.7 HU. Both manual and automated CT methods had almost perfect agreement with MRI (κ = 0.90) and substantial agreement with pathology (κ = 0.77). In the second cohort, the manual and automated CT methods had almost perfect agreement (ICC = 0.94, κ = 0.87). LoA were −10.6 to 5.2 HU. Conclusion: Automated measurements of liver attenuation from LDCT scans can be used to identify moderate-to-severe HS on LDCT.",
keywords = "Hepatic steatosis, Image analysis, Low-dose CT, Lung screening",
author = "Artit Jirapatnakul and Reeves, {Anthony P.} and Sara Lewis and Xiangmeng Chen and Teng Ma and Rowena Yip and Xing Chin and Shuang Liu and Perumalswami, {Ponni V.} and Yankelevitz, {David F.} and Michael Crane and Branch, {Andrea D.} and Henschke, {Claudia I.}",
note = "Funding Information: • Dr. Anthony P. Reeves is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are non-exclusively licensed to General Electric. As an inventor of these patents, Dr. Reeves is entitled to a share of any compensation which CRF may receive from its commercialization of these patents. Dr. Reeves is the President of D4Vision and has stock ownership in Visiongate, Inc. • Dr. David F. Yankelevitz is a named inventor on a number of patents and patent applications relating to the evaluation of diseases of the chest including measurement of nodules. Some of these, which are owned by Cornell Research Foundation (CRF), are non-exclusively licensed to General Electric. As an inventor of these patents, Dr. Yankelevitz is entitled to a share of any compensation which CRF may receive from its commercialization of these patents. He is also an equity owner in Accumetra, a privately held technology company committed to improving the science and practice of image-based decision making. Dr. Yankelevitz also serves on the advisory board of GRAIL. • Dr. Claudia I. Henschke is the President and serves on the board of the Early Diagnosis and Treatment Research Foundation. She receives no compensation from the Foundation. The Foundation is established to provide grants for projects, conferences, and public databases for research on early diagnosis and treatment of diseases. Dr. Claudia Henschke is also a named inventor on a number of patents and patent applications relating to the evaluation of pulmonary nodules on CT scans of the chest which are owned by Cornell Research Foundation (CRF). Since 2009, Dr. Henschke does not accept any financial benefit from these patents including royalties and any other proceeds related to the patents or patent applications owned by CRF. • Other authors declare no conflicts of interest. Funding Information: This study was funded in part by Flight Attendant Medical Research Institute (FAMRI) and WTC U01OH011489 . Publisher Copyright: {\textcopyright} 2019 Elsevier B.V.",
year = "2020",
month = jan,
doi = "10.1016/j.ejrad.2019.108723",
language = "English",
volume = "122",
journal = "European Journal of Radiology",
issn = "0720-048X",
publisher = "Elsevier Ireland Ltd",
}